Abivax

• ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Not authorised
  2022-500535-36-00 Phase III 6 countries OBEFAZIMOD
• ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Not authorised
  2022-500536-11-00 Phase III 6 countries OBEFAZIMOD
• ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised
  2022-500537-84-00 Phase III 6 countries OBEFAZIMOD
• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting
  2023-508234-34-00 Phase II 11 countries OBEFAZIMOD
• Effects of ABX464 during long-term treatment in patients with moderate to severe ulcerative colitis Ended
  2023-507974-42-00 Phase II 11 countries OBEFAZIMOD
• A Phase I study to evaluate the pharmacokinetics, safety and tolerability of multiple oral doses of obefazimod in participants with renal im… Ended
  2024-514561-20-00 Phase I (Other) 1 country
• A Phase 1, 2-part, open-label, single-sequence study to investigate the effect of single and multiple doses of obefazimod on the pharmacokin… Ended
  2023-509226-21-00 Phase I (Other) 1 country
• A study to investigate the effects of multiple doses of obefazimod on a combined oral contraceptive (ethinyl estradiol/drospirenone) in hea… Ended
  2023-505297-15-00 Phase I (Other) 1 country
• A Phase I study to evaluate the pharmacokinetics, safety, and tolerability of multiple oral doses of obefazimod in patients with mild and mo… Ended
  2023-505299-31-00 Phase I (Other) 1 country
• ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Ended
  2022-500535-36-01 Phase III 13 countries OBEFAZIMOD
• ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended
  2022-500536-11-01 Phase III 14 countries OBEFAZIMOD

Showing 1–11 of 11 trials